On Friday, iBio Inc (NASDAQ: IBIO) opened lower -8.94% from the last session, before settling in for the closing price of $6.15. Price fluctuations for IBIO have ranged from $1.05 to $6.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -18.92% over the past five years. Company’s average yearly earnings per share was noted 60.55% at the time writing. With a float of $9.27 million, this company’s outstanding shares have now reached $9.87 million.
Let’s look at the performance matrix of the company that is accounted for 19 employees. In terms of profitability, gross margin is 209.87%, operating margin of -4134.67%, and the pretax margin is -3795.73%.
iBio Inc (IBIO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of iBio Inc is 6.12%, while institutional ownership is 26.65%. The most recent insider transaction that took place on Jan 10 ’25, was worth 25,000. In this transaction Chief Financial Officer of this company bought 9,191 shares at a rate of $2.72, taking the stock ownership to the 11,139 shares. Before that another transaction happened on Jan 10 ’25, when Company’s insider bought 9,191 for $2.72, making the entire transaction worth $25,000. This insider now owns 18,316 shares in total.
iBio Inc (IBIO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.55% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.01% during the next five years compared to 57.55% growth over the previous five years of trading.
iBio Inc (NASDAQ: IBIO) Trading Performance Indicators
Check out the current performance indicators for iBio Inc (IBIO). In the past quarter, the stock posted a quick ratio of 1.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 145.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.38 in one year’s time.
Technical Analysis of iBio Inc (IBIO)
iBio Inc (NASDAQ: IBIO) saw its 5-day average volume 0.92 million, a positive change from its year-to-date volume of 0.54 million. As of the previous 9 days, the stock’s Stochastic %D was 75.39%. Additionally, its Average True Range was 0.64.
During the past 100 days, iBio Inc’s (IBIO) raw stochastic average was set at 73.25%, which indicates a significant increase from 63.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 161.19% in the past 14 days, which was higher than the 93.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.44, while its 200-day Moving Average is $2.56. Nevertheless, the first resistance level for the watch stands at $6.07 in the near term. At $6.54, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.92. If the price goes on to break the first support level at $5.22, it is likely to go to the next support level at $4.84. The third support level lies at $4.37 if the price breaches the second support level.
iBio Inc (NASDAQ: IBIO) Key Stats
There are currently 9,875K shares outstanding in the company with a market cap of 55.30 million. Presently, the company’s annual sales total 230 K according to its annual income of -24,910 K. Last quarter, the company’s sales amounted to 200 K and its income totaled -4,360 K.
